

Type of article: Research article

Title: EXPANDING THE VECTOR CONTROL TOOLBOX FOR MALARIA ELIMINATION: A SYSTEMATIC REVIEW OF THE EVIDENCE

Authors: Yasmin A Williams^{1*†}, Lucy S Tusting^{2†}, Sophia Hocini, Patricia M Graves³, Gerry F Killeen^{4, 5}, Immo Kleinschmidt^{6, 7, 8}, Fredros O Okumu⁴, Richard GA Feachem¹, Allison Tatarsky¹, Roly D Gosling¹

†Contributed equally

Number of tables: 3

Number of figures: 2

Author affiliations: **1** Malaria Elimination Initiative, Global Health Group, University of California, San Francisco, USA, **2** Big Data Institute, Nuffield Department of Medicine, University of Oxford, UK, **3** College of Public Health, Medical and Veterinary Sciences and Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia, **4** Environmental Health and Ecological Sciences Department, Ifakara Health Institute, Tanzania, **5** Vector Biology Department, Liverpool School of Tropical Medicine, UK, **6** MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, UK (I Kleinschmidt, PhD), **7** School of Pathology, Faculty of Health Sciences, University of Witwatersrand, South Africa, **8** Elimination 8, Windhoek, Namibia

Corresponding author:

Yasmin A Williams

Email: Yasmin.Williams@ucsf.edu

Telephone: +1 415 502 5495

Keywords: malaria, malaria elimination, vector control, vector control tools, vector-borne diseases

1 **Abstract**

2 **Background**

3 Additional vector control tools (VCTs) are needed to supplement insecticide-treated nets (ITNs) and
4 indoor residual spraying (IRS) to achieve malaria elimination in many settings. To identify options for
5 expanding the malaria vector control toolbox, we conducted a systematic review of the availability and
6 quality of the evidence for 21 malaria VCTs, excluding ITNs and IRS.

7 **Methods**

8 Six electronic databases and grey literature sources were searched from January 1, 1980 to September 28,
9 2015 to identify systematic reviews, Phase I-IV studies, and observational studies that measured the effect
10 of malaria VCTs on epidemiological or entomological outcomes across any age groups in all malaria-
11 endemic settings. Eligible studies were summarized qualitatively, with quality and risk of bias
12 assessments undertaken where possible. Of 17,912 studies screened, 155 were eligible for inclusion and
13 were included in a qualitative synthesis.

14 **Results**

15 Across the 21 VCTs, we found considerable heterogeneity in the volume and quality of evidence, with
16 seven VCTs currently supported by at least one Phase III community-level evaluation measuring
17 parasitologically-confirmed malaria incidence or infection prevalence (insecticide-treated clothing and
18 blankets, insecticide-treated hammocks, insecticide-treated livestock, larval source management (LSM),
19 mosquito-proofed housing, spatial repellents, and topical repellents). The remaining VCTs were
20 supported by one or more Phase II (n=13) or Phase I evaluation (n=1). Overall the quality of the evidence
21 base remains greatest for LSM and topical repellents, relative to the other VCTs evaluated, although
22 existing evidence indicates that topical repellents are unlikely to provide effective population-level
23 protection against malaria.

24 **Conclusions**

25 Despite substantial gaps in the supporting evidence, several VCTs may be promising supplements to ITNs
26 and IRS in appropriate settings. Strengthening operational capacity and research to implement
27 underutilized VCTs, such as LSM and mosquito-proofed housing, using an adaptive, learning-by-doing
28 approach, while expanding the evidence base for promising supplementary VCTs that are locally tailored,
29 should be considered central to global malaria elimination efforts.

30 **Introduction**

31 Great advances have been made in malaria control and elimination, with a 37% global decline in malaria
32 incidence during 2000-2015 (Global Malaria Programme, 2015). New targets include the elimination of
33 malaria from at least 35 countries by 2030 (Global Malaria Programme, 2017), with renewed calls for
34 eradication within a generation (Gates and Chambers, 2015). In sub-Saharan Africa (SSA), vector control
35 with insecticide-treated nets (ITNs) and indoor residual spraying (IRS) has averted an estimated 524
36 million malaria cases since 2000 (Global Malaria Programme, 2015). However, after an extraordinary
37 period of success in global malaria control, progress has stalled with 216 million malaria cases in 2016,
38 up 5 million cases from 2015 (Global Malaria Programme, 2017). There remain important obstacles to
39 achieving and sustaining progress towards elimination, including operational inefficiencies that lead to
40 low effective coverage (Bhatt et al., 2015), insecticide resistance (Ranson and Lissenden, 2016), and
41 residual transmission mediated by mosquito behaviours such as outdoor biting and resting, feeding upon
42 animals, and early exit from houses immediately after entering, which are not effectively targeted by
43 ITNs and IRS (Killeen; 2014, Govella and Ferguson, 2012).

44

45 To achieve malaria elimination goals in the face of such challenges, what evidence-based vector control
46 tools (VCTs) can national malaria control and elimination programs access today or within the next
47 decade to supplement ITNs and IRS? To date, ITNs and IRS are the only VCTs to have been
48 recommended for wide-scale implementation by the World Health Organization (WHO), while larval
49 source management (LSM) and personal protection measures against mosquitoes are recommended in
50 some settings (World Health Organization, 2015). Recognising the need for additional VCTs, WHO
51 recently established mechanisms for expedited vector control recommendations, including new technical
52 expert panels (Malaria Policy Advisory Committee, 2015; WHO Vector Control Advisory Group, 2013)
53 and the Innovation to Impact (I2I) initiative to support VCT development and access (Innovation to
54 Impact (I2I), 2016). Recent calls for novel vector control interventions with proven effectiveness elevated
55 the global demand for new VCTs (World Health Organization, 2017; malERA Refresh Consultative Panel

56 on Tools for Malaria Elimination, 2017). Here, to guide the identification of promising VCTs to expand
57 the vector control toolbox for malaria elimination, we conducted a systematic review to collate published
58 and unpublished evidence on the effect of selected VCTs on confirmed clinical malaria and malaria
59 infection in people of any ages and on *Anopheles*-specific entomological outcomes in malaria-endemic
60 regions. This is the first study to collate systematically the evidence across the spectrum of malaria vector
61 control, excluding ITNs and IRS. Innovations in ITN and IRS technologies are also important
62 contributions to the vector control toolbox (e.g. new active ingredients, insecticide combinations, and
63 application technologies, among others) with significant product development and evaluation efforts
64 underway but are outside the scope of this review (Innovative Vector Control Consortium, 2016;
65 Wagman et al., 2018).

66

67 **Methods**

68 We conducted a systematic review of the literature to summarize the availability and quality of the
69 evidence for 21 malaria VCTs, excluding ITNs and IRS (Table 1). We followed guidelines of the
70 Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) (Additional File 1)
71 (Wilson et al., 2015). The candidate VCTs for evaluation were selected through consultation with experts
72 (including a meeting held on June 1-3, 2015 in San Francisco, US) and the review of policy documents
73 (WHO Vector Control Advisory Group, 2013; WHO Vector Control Advisory Group, 2014).

74

75 [Insert Table 1 here]

76

77 ***Eligibility criteria***

78 Studies were included that evaluated any VCT targeting *Anopheles* mosquitoes in Table 1 and that met
79 the eligibility criteria described in Table 2. Eligible study designs were categorized as observational,
80 Phase I, Phase II, or Phase III studies. Observational studies included those with case-control, cohort or
81 cross-sectional designs. Phase I studies were defined as laboratory assays to determine the mode of

82 action. Phase II were defined as semi-field, experimental hut, and small-scale field studies, generally with
83 entomological outcomes. Finally, Phase III studies were defined as trials measuring the efficacy of the
84 VCT against epidemiological outcomes under optimal conditions (Wilson et al., 2015). Categories based
85 on level of evidence were used since level of evidence is the basis for WHO policy recommendation.

86

87 [Insert Table 2 here]

88

89 *Search strategy and selection criteria*

90 PubMed; EMBASE; LILACS; the Cochrane Infectious Diseases Group Specialized Register; Cochrane
91 Central Register of Controlled Trials (CENTRAL), published in The Cochrane Library; and the Meta-
92 Register of Controlled Trials (mRCT) were searched for studies published in English from January 1,
93 1980 to September 28, 2015 with the search terms described in Additional File 2. Search dates were
94 restricted because systematic reviews included in this review captured the historical evidence on older
95 VCTs, including LSM. Additionally, we searched reference lists of identified studies and contacted
96 authors and field experts for unpublished data. To identify studies in progress, we searched the
97 ClinicalTrials.gov registry. YAW and SH independently screened titles and abstracts, followed by full-
98 text screening of relevant studies for eligibility using a standard form in Qualtrics (Qualtrics, Provo, UT).
99 Disagreements were resolved by LST.

100

101 *Data abstraction*

102 Study characteristics (including participants, intervention, control group, outcomes, and sample size, as
103 applicable) and findings were double-entered into a standard form in Microsoft Excel by YAW and
104 verified by LST. Since we aimed to assess evidence availability, not VCT efficacy, we did not combine
105 studies in a meta-analysis. Instead, for each VCT we summarized the current evidence by the number and
106 type of completed studies and, where possible, stratified this information by outcome. We presented in
107 tables all eligible studies for every VCT, except for VCTs with a recent (≤ 5 years old) high-quality

108 systematic review (Measurement Tool to Assess Systematic Reviews (AMSTAR) (Shea et al., 2007)
109 score $\geq 50\%$; see below), for which we presented only the systematic review (Wilson et al., 2015).

110

111 *Quality of systematic reviews and risk of bias in Phase III studies*

112 The quality of systematic reviews was assessed using the AMSTAR tool (Shea et al., 2007). Risk of bias
113 for randomized controlled trials (RCTs), controlled before-and-after studies (CBA), cross-over studies,
114 and interrupted time-series studies was assessed using the Effective Practice and Organization of Care
115 (EPOC) tool (Effective Practice and Organisation of Care (EPOC), 2015). Risk of bias was not assessed
116 for Phase I, Phase II, or observational studies due to wide heterogeneity in study designs. We did not
117 perform a statistical test for publication bias because we did not conduct any meta-analyses.

118

119 **Results**

120 The search results yielded 17,912 unique studies after removing duplicates (Figure 1). A total of 155
121 studies met the eligibility criteria and were included in the qualitative synthesis; these were of the
122 following designs: systematic reviews (n=7); Phase III (n=7), Phase II (n=76), and Phase I (n=54)
123 experimental studies; and cross-sectional (n=7), case-control (n=3), and cohort (n=1) observational
124 studies (Figure 2, Additional File 3). Methodological quality was variable across the seven eligible
125 systematic reviews, with AMSTAR scores ranging from 18% to 100% (Additional File 4A). The
126 systematic reviews of LSM (n=2), mosquito-proofed housing (n=1), and topical repellents (n=1) were
127 determined to be of the highest quality (AMSTAR scores $\geq 50\%$), while those of spatial repellents (n=2)
128 and zooprophyllaxis (n=1) were judged to be of lower quality. Of the 21 VCTs evaluated, we identified
129 seven with one or more completed Phase III study, including some that were included in systematic
130 reviews: LSM, insecticide-treated clothing and blankets, insecticide-treated hammocks, insecticide-
131 treated livestock, mosquito-proofed housing, spatial repellents, and topical repellents; with recent, high-
132 quality systematic reviews available for LSM, mosquito-proofed housing, and topical repellents (Table 3).

133

134 [Insert Figure 1 here]

135

136 [Insert Figure 2 here]

137

138 [Insert Table 3 here]

139

140 ***VCTs with a recent systematic review***

141 *Larval source management (LSM):* A 2013 Cochrane review compared biological control with
142 larvivorous fish to biological control without larvivorous fish (Walshe et al., 2013). No eligible studies
143 included in this review measured malaria incidence, entomological inoculation rate (EIR), or adult vector
144 density (Table 3). Nine quasi-experimental studies measured larval mosquito density, with variable
145 effects. A second 2013 Cochrane review compared LSM (excluding biological control with larvivorous
146 fish) with no LSM (Tusting et al., 2013). Compared to the control, LSM reduced malaria incidence by
147 74% in two cluster RCTs, but there was no consistent effect on malaria incidence in three CBA studies.
148 GRADE quality (Atkins et al., 2004) of evidence ranged from very low to moderate. Parasite prevalence
149 was reduced by 89% in another cluster-RCT and by an average of 68% in five CBA studies. GRADE
150 quality of evidence was assessed to be moderate for both subgroups.

151

152 *Mosquito-proofed housing:* A 2015 systematic review included one Phase III RCT and four observational
153 studies in a meta-analysis comparing screened with unscreened housing, in which findings on the effect
154 on clinical malaria, malaria infection, and anaemia in children were inconsistent (Table 3) (Tusting et al.,
155 2015). A further 15 observational studies were included in a meta-analysis comparing ‘modern’ housing
156 (e.g. brick or cement walls and metal roofs) with ‘traditional’ housing (e.g. mud walls, thatched roofs,
157 open eaves, and no screening) (Tusting et al., 2015). Modern housing was associated with a 45-65%
158 lower odds of clinical malaria and 47% lower odds of malaria infection, compared to traditional housing,
159 although the GRADE quality of evidence was assessed to be very low.

160

161 *Topical repellents:* In a systematic review of experimental studies comparing topical repellents with no
162 repellent or placebo repellents (Wilson et al., 2014), the risk of *P. falciparum* malaria or infection was
163 reduced by 18% in six RCTs and one CBA. *P. vivax* malaria or infection was reduced by 20% in five
164 RCTs and one CBA, compared to the control, but neither reduction was statistically significant. EPOC
165 risk of bias in the included studies ranged from low to unclear (Table 3).

166

167 ***Other VCTs with a Phase III evaluation***

168 *Insecticide-treated clothing and blankets:* Malaria incidence was measured in two RCTs with low to
169 moderate risk of bias, where the effect of insecticide-treated clothing and blankets ranged from an 81%
170 decrease to no effect, compared to the control (Table 3) (Macintyre et al., 2003; Rowland et al., 1999).
171 Outcomes assessed by the four Phase II studies included parasite prevalence (n=2) and adult mosquito
172 mortality (n=2) (Additional File 3B).

173

174 *Insecticide-treated hammocks:* Malaria incidence and parasite prevalence were measured in two Phase III
175 RCTs, with EPOC risk of bias for both studies assessed to be low (Table 3). In Venezuela, insecticide-
176 treated hammocks reduced malaria incidence by 56% and parasite prevalence by 83%, compared to the
177 control (Magris et al., 2007), and in Vietnam a greater reduction in malaria incidence and parasite
178 prevalence was observed in the intervention arm than in the control (footnote to Table 3) (Thang et al.,
179 2009). One Phase II study measured adult *An. gambiae* mortality, hut entry, and blood feeding inhibition
180 (Additional File 3C).

181

182 *Insecticide-treated livestock:* Malaria incidence and parasite prevalence were measured in one Phase III
183 cross-over study, with EPOC risk of bias assessed to be moderate, in which insecticide-treated livestock
184 reduced malaria incidence by 31-56% and parasite prevalence by 40-54% compared to the control, though
185 the effect was not consistently significant (Table 3) (Rowland et al., 2001). Entomological outcomes

186 measured in five Phase II studies included adult mosquito mortality and blood feeding preference
187 (Additional File 3C).

188
189 *Spatial repellents:* Two systematic reviews included laboratory and Phase II field studies only, with no
190 meta-analyses (Table 3) (Lawrence and Croft, 2004; Ogoma et al., 2012). No eligible studies measured
191 the effect of spatial repellents on malaria incidence. Parasite prevalence was measured in two RCTs, with
192 the EPOC risk of bias assessed to be low for both studies, and in one cross-sectional study. In the RCTs,
193 transfluthrin coils reduced parasite prevalence by 77% compared to long-lasting insecticide-treated nets
194 (LLINs) alone and by 94% when combined with LLINs, compared to no intervention in China (Hill et al.,
195 2014); metofluthrin mosquito coils reduced parasite prevalence by 52% compared to a placebo in
196 Indonesia (Syafruddin et al., 2014). Entomological outcomes measured in 23 Phase II studies and one
197 Phase I study included human biting rate (HBR), adult mosquito mortality, and repellency (Additional
198 File 3C).

199
200 ***VCTs with no Phase III evaluation***

201 Fourteen VCTs had Phase I, II, and/or observational evidence only: adult sterilization by contamination,
202 attractive toxic sugar baits (ASTBs), other attract-and-kill mechanisms, biological control of adult
203 vectors, eave tubes and eave baffles, endectocide administration in humans, endectocide administration in
204 livestock, genetic modification, insecticide-treated durable wall linings, insecticide-treated fencing,
205 larvicide application by autodissemination, push-pull systems, space spraying (ground application), and
206 zooprophyllaxis (Figure 2, Additional File 3C, Additional File 3D). For these VCTs we included a total of
207 103 studies, comprising 42 Phase II, 51 Phase I, and 10 observational studies. All VCTs had at least one
208 eligible Phase II study, except endectocide administration in humans. Three VCTs had at least one
209 eligible observational study: endectocide administration in humans, spatial repellents, and
210 zooprophyllaxis. For zooprophyllaxis, we also identified one systematic review (AMSTAR score 18%),
211 which reported no meta-analysis (Donnelly et al., 2015). Entomological outcomes were measured for all

212 VCTs, while epidemiological outcomes were measured for two VCTs only (space spraying and
213 zooprophyllaxis).

214

215 **Discussion**

216 To address the challenges of insecticide resistance and residual transmission, strengthen malaria vector
217 control, and maintain progress towards elimination, additional malaria vector control tools are needed. In
218 this systematic review assessing the availability and quality of evidence for 21 supplementary VCTs, we
219 included 155 studies dating from January 1, 1980 to September 28, 2015. This is the first study to collate
220 evidence systematically across the malaria vector control toolbox beyond ITNs and IRS. Our study
221 highlights the expanding pipeline of research into supplementary VCTs, while identifying substantial
222 heterogeneity in the availability and quality of the evidence required by WHO to provide normative
223 guidance on implementation (i.e. standardized epidemiological data from Phase III trials in multiple
224 settings) (WHO Vector Control Advisory Group, 2013; Malaria Policy Advisory Committee, 2012).

225

226 For each VCT, we summarized the current evidence by the number and quality of studies and stratified
227 this information by outcome where possible since this information forms the basis of WHO policy
228 considerations. Within this framework, the evidence base was the most extensive for LSM and topical
229 repellents, which both have multiple published Phase III evaluations and recent systematic reviews
230 assessed to be of high methodological quality. While the evidence for LSM was assessed to be of very
231 low to moderate quality (Tusting et al., 2013), combinations of larviciding and environmental
232 management have been effective in reducing malaria transmission in certain eco-epidemiological settings
233 in Africa and Asia and larviciding has been recommended by WHO as a supplementary intervention in
234 SSA since 2013 (Global Malaria Programme, 2015). This recommendation is limited to discrete settings
235 where habitats are relatively ‘few, fixed, and findable’; far narrower than settings in high-income
236 countries where larviciding is used routinely and successfully for mosquito and disease control (Global
237 Malaria Programme, 2015). In contrast, the evidence for topical repellents is of relatively high quality

238 (Wilson et al., 2014) but indicates that topical repellents are unsuitable as a large-scale public health
239 intervention, although they can provide individual protection against mosquitoes (Wilson et al., 2014).
240 We identified five further VCTs with at least one Phase III evaluation with epidemiological outcomes:
241 insecticide-treated clothing and blankets, insecticide-treated hammocks, insecticide-treated livestock,
242 mosquito-proofed housing, and spatial repellents. These VCTs offer additional options for supplementing
243 ITNs and IRS, often with complementary modes of action. Further Phase III community level trials will
244 help to clarify their roles in malaria vector control in different epidemiological settings (Killeen, 2014;
245 Lobo NF et al. 2014; Pinder et al., 2016).

246
247 Our assessment of evidence was based on study design and outcomes, but in the future it may be
248 necessary to consider evidence complementary to standard epidemiological assessments (Vontas et al.,
249 2014). First, making recommendations across diverse transmission settings and local vector ecologies is
250 difficult; what works in one or two settings may not work in all settings. Growing understanding of the
251 genetic diversity among *Anopheles* further contributes to this complexity (The *Anopheles gambiae* 1000
252 Genomes Consortium, 2017). Trends in malaria transmission and performance of VCTs are also
253 confounded by longer-term changes in environmental and infrastructural landscapes and climate (Snow et
254 al., 2017). Although Cochrane reviews remain the gold standard in evidence-based policy, it is often
255 inappropriate to combine findings from studies across different eco-epidemiological settings when VCT
256 efficacy is tied to local transmission ecology (Walshe et al., 2013; Tusting et al., 2013). Second, some
257 emerging VCTs remain years away from accumulating a full dossier of epidemiological evidence, and
258 although further Phase III studies are planned (Thomas M et al., 2015), nearing completion (Mtove et al.,
259 2016), or recently concluded (Homan et al., 2017), we identified fourteen VCTs for which no Phase III
260 epidemiological data were available within the search dates. Demonstrating protection against disease
261 and/or infection is critical before any VCTs can be recommended for large-scale deployment (Wilson et
262 al., 2015). However, in some circumstances, evidence of effect might be built by adopting underutilised
263 VCTs as supplementary interventions within a ‘learning-by-doing’ framework. This iterative, adaptive

264 approach involves the incorporation of rigorous monitoring and evaluation of epidemiological and
265 entomological outcomes in control and intervention areas to support the gradual scale-up of additional
266 VCTs within existing programme infrastructure, such as through adaptable Phase IV effectiveness studies
267 (Killeen, 2014; Wilson et al., 2015; Global Malaria Programme, 2014). For example, while only one RCT
268 of house screening for malaria control has been completed (Kirby et al., 2009), a large body of
269 observational evidence suggests that screened housing is associated with reduced malaria risk and
270 national malaria control programs are encouraged to explore opportunities to build ‘healthier’ housing
271 (Roll Back Malaria, 2015). This approach would also allow for a more rapid expansion of the evidence
272 base across a wider diversity of eco-epidemiological settings to inform locally-tailored solutions as well
273 as iteration over time as the transmission landscape changes.

274

275 Direct transition to Phase IV ‘learning-by-doing’ approaches are controversial and inappropriate for
276 VCTs with a poor or absent evidence base (Wilson et al., 2015). The history of ITNs and IRS
277 demonstrates varying routes to establishing effectiveness against malaria disease or infection; ITNs
278 underwent rigorous evaluation through Phase III RCTs (Darriet et al., 1984), while IRS effectiveness was
279 established decades before evaluation in RCTs (Sadasivaia et al., 2007). Given adequate funding,
280 promising new VCTs should reach approval far faster than ITNs, but depending on the entomological
281 mode of action, efficacy of a VCT in one ecological setting is not always guaranteed elsewhere. Recent
282 examples illustrate the importance of demonstrating efficacy against epidemiological as well
283 entomological outcomes. Topical repellents reduce vector biting, but it took a cluster RCT with
284 epidemiological outcomes to show their unsuitability as a generalizable public health intervention due to
285 the high user compliance required (Messenger, 2012). Conversely, odour baited traps have recently been
286 shown to reduce malaria infection prevalence in a rigorous RCT, but entomological data from that study
287 suggest caution before deploying this VCT at scale in different settings since the traps were largely
288 effective against *An. funestus* only (Homan et al., 2017).³⁶ Such information may be obtainable through
289 ‘learning-by-doing’ evaluations, as long as evaluations of outcomes are of high quality. Research

290 institutions will need to support control programs in design, technical capacity, and analysis to ensure
291 meaningful findings are obtained from Phase IV effectiveness evaluations. A recent call for more
292 adaptive strategies responding to shifting transmission also highlights the need for optimizing
293 combinations of interventions to maximize impact and mitigate the risk of insecticide resistance (malERA
294 Refresh Consultative Panel on Tools for Malaria Elimination, 2017).

295
296 Despite limited evidence on their efficacy against malaria, the fourteen VCTs with no complete Phase III
297 evaluation offer diverse modes of action to complement those of ITNs and IRS within a comprehensive
298 intervention package. Some may only be suitable for niche application, for example, insecticide-treated
299 clothing may be effective for individuals working outdoors at night, but not as a general public health
300 intervention. Others such as insecticide-treated durable wall linings (which are impregnable with
301 alternative insecticides to those used for IRS) might reduce reliance on the main classes of insecticides
302 currently available for ITNs and IRS; a multi-country Phase III evaluation is currently underway
303 (Messenger, 2012). Similarly, administration of endectocides such as ivermectin to people or livestock
304 could circumvent insecticide resistance and target zoophagic behaviours in vectors, although
305 epidemiological effect remains to be demonstrated (Chaccour et al., 2015; Foy et al., 2011). Some
306 emerging VCTs might reduce transmission by vectors biting outdoors, including larvicide application by
307 autodissemination using pyriproxyfen, which targets immature mosquitoes regardless of adult biting and
308 resting behaviour (Mbare et al., 2014). Some emerging VCTs exploit vulnerability in alternative vector
309 life stages to those targeted by ITNs and IRS. ATSBs, which target sugar feeding, consistently reduced
310 adult mosquito density and HBR in Phase II studies in Israel, Mali, and the USA. However, Phase III
311 trials of ATSBs with epidemiological outcomes are certainly needed. Genetic modification of mosquitoes
312 aims to suppress populations thereby reducing vectorial competence (Alphey and Alphey, 2014), but our
313 review highlights how such approaches have yet to progress fully beyond laboratory evaluations.

314
315 Overall the expansion of research on supplementary VCTs is encouraging, but arguably the first step to

316 strengthening vector control for malaria elimination is to improve operational capacity to deliver and
317 sustain existing interventions effectively (Brady et al., 2016). For example, major inefficiencies persist
318 within LLIN delivery systems across SSA, limiting population access (Bhatt and Gething, 2014). There
319 are also opportunities to explore new or improved delivery mechanisms for existing supplementary
320 interventions, such as aerial application of larvicides (Knapp et al., 2015). Some VCTs may not be highly
321 effective individually, but could potentially be highly effective when used in combinations. The malERA
322 updated research agenda highlights this need for optimizing combinations of interventions to maximize
323 impact and mitigate the risk of insecticide resistance (malERA Refresh Consultative Panel on Tools for
324 Malaria Elimination, 2017). Use of mathematical models could help to address such questions, where no
325 epidemiological evidence is available (Kiware et al., 2017). Critical to improving vector control is the
326 development of strong local entomological capacity (Mnzava et al., 2014), together with a much more
327 significant focus on community engagement and effective integration of control across vector-borne
328 diseases and government sectors (Brady et al., 2016; World Health Organization, 2009; World Health
329 Organization, 2017).

330

331 Our study has several limitations. First, our VCTs of interest were selected *a priori* through expert
332 consultation and are not an exhaustive list. Second, our search was restricted to English language papers
333 only, potentially excluding experiences from some regions. Third, we did not combine data across studies
334 in a meta-analysis, precluding evaluation of effect on entomological and epidemiological outcomes and
335 statistical tests for publication bias. Fourth, for studies with entomological outcomes there was no
336 mechanism to standardize outcomes and assess how heterogeneity in the choice of control affected study
337 findings. Fifth, this review focused on individual interventions and did not consider the potential benefits
338 of combining two or more of the new VCTs in communities already using ITNs and/or IRS. Finally, we
339 did not assess methodological quality and risk of bias in Phase I and II studies due to heterogeneity in
340 study design.

341

342 In conclusion, our review highlights the expanding pipeline of research into new and underutilized
343 approaches to malaria vector control and the critical need to prioritize and fund robust evaluation of
344 supplementary VCTs. Despite substantial gaps in the supporting evidence, several VCTs are promising
345 supplements to ITNs and IRS. Strengthening operational capacity to implement and evaluate
346 underutilized VCTs, such as LSM and mosquito-proofed housing, while expanding the evidence base for
347 newer VCTs through strategic assessment of existing evidence and rigorous epidemiological evaluation,
348 should be central to global malaria control and elimination efforts. A practical, program-oriented research
349 agenda to evaluate where, when, and in what combination to use these supplemental VCTs should be
350 developed and prioritized for funding and implementation in the near-term. Future research should also
351 assess the cost, cost-effectiveness, scalability, and availability of supplemental VCTs to inform vector
352 control strategies and intervention selection as countries and regions accelerate toward elimination.

353 **Additional files**

354 **Additional file 1:** PRISMA statement

355 **Additional file 2:** Search strategy

356 **Additional file 3:** Characteristics and summary of findings of systematic reviews, Phase I-III, and
357 observational studies

358 **Additional file 4:** Quality assessment of systematic reviews and risk of bias in Phase III studies

359

360 **Contributors**

361 RDG, AT, and GFK conceived of the study. YAW, LST, RDG, GFK, and AT developed the study
362 design. YAW, LST, and SH searched the literature. YAW and LST extracted the data and prepared the
363 manuscript. PMG advised on the systematic review. All authors had access to study data and reviewed the
364 final manuscript. All authors read and approved the final manuscript.

365

366 **Author's information**

367 Yasmin A Williams and Lucy S Tusting are joint first authors.

368

369 **Acknowledgements**

370 This work was supported by the University of California, Group Health Group Malaria Elimination
371 Initiative through funding from The Parker Foundation (www.parker.org). LST is a Skills Development
372 Fellow (#N011570) jointly funded by the UK Medical Research Council (MRC) and the UK Department
373 for International Development (DFID) under the MRC/DFID Concordat agreement
374 (<http://www.mrc.ac.uk/>). FOO is also supported by a Wellcome Trust Intermediate Research Fellowship
375 (#WT102350/Z/13/Z). We thank Dr William Hawley for his review of the manuscript, Dr Jimée Hwang
376 for input on the study protocol, and Nicolas Simon for his help with study screening.

377

378 **Conflict of interests**

379 The authors declare that they have no conflict of interests. The study sponsors had no role in study design,
380 in the collection, analysis and interpretation of data, in writing the report, and in the decision to submit for
381 publication.

References

- 382 Alphey, L., & Alphey, N. (2014). “Five things to know about genetically modified (GM) insects for
383 vector control”. *PLoS Pathog*, **10**(3), e1003909.
- 384 Atkins, D., Best, D., Briss, P.A., Eccles, M., Falck-Ytter, Y., Flottorp, S., Guyatt, G.H., Harbour, R.T.,
385 Haugh, M.C., Henry, D., Hill, S., Jaeschke, R., Leng, G., Liberati, A., Magrini, N., Mason, J.,
386 Middleton, P., Mrukowicz, J., O’Connell, D., Oxman, A.D., Phillips, B., Schünemann, H.J.,
387 Edejer, T., Varonen, H., Vist, G.E., Williams, J.W. Jr., & Zaza, S.; GRADE Working Group.
388 (2004). “Grading quality of evidence and strength of recommendations”. *BMJ*, **328**(7454), 1490.
- 389 Bhatt, S. & Gething, P.W. (2014). “Insecticide-treated nets (ITNs) in Africa 2000-2016: coverage, system
390 efficiency and future needs for achieving international targets”. *Malar J*, **13**, O29.
- 391 Bhatt, S., Weiss, D. J., Mappin, B., Dalrymple, U., Cameron, E., Bisanzio, D., Smith, D. L., Moyes, C. L.,
392 Tatem, A. J., Lynch, M., Fergus, C. A., Yukich, J., Bennett, A., Eisele, T. P., Kolaczinski, J.,
393 Cibulskis, R. E., Hay, S. I. & Gething, P. W. (2015). “Coverage and system efficiencies of
394 insecticide-treated nets in Africa from 2000 to 2017”. *eLife*, **4**.
- 395 Brady, O.J., Godfray, H.C.J., Tatem, A.J., Gething, P.W., Cohen, J.M., Mckenzie, F.E., Perkins, T.A.,
396 Reiner, R.C., Tusting, L.S., Sinka, M.E., Moyes, C.L., Eckhoff, P.A., Scott, T.W., Lindsay, S.W.,
397 Hay, S.I. & Smith, D.L. (2016). “Vectorial capacity and vector control: reconsidering sensitivity
398 to parameters for malaria elimination”. *Trans R Soc Trop Med Hyg*, **110**(2), 107–17.
- 399 Chaccour, C.J., Rabinovich, N.R., Slater, H., Canavati, S. E., Bousema, T., Lacerda, M., Ter Kuile, F.,
400 Drakeley, C., Bassat, Q., Foy, B. D. & Kobylinski, K. (2015). “Establishment of the ivermectin
401 research for malaria elimination network: updating the research agenda”. *Malar J*, **14**, 243.
- 402 Darriet, F. D. R., Robert, V., Vien, N. T., & Carnevale, P. (1984). “Evaluation of the efficacy of
403 permethrin-impregnated intact and perforated mosquito nets against vectors of malaria”. Geneva:
404 World Health Organization.
- 405 Donnelly, B., Berrang-Ford, L., Ross, N. A. & Michel, P. (2015). “A systematic, realist review of
406 zooprophylaxis for malaria control”. *Malar J*, **14**, 313.
- 407 Foy, B.D., Kobylinski, K.C., Da Silva, I.M., Rasgon, J.L. & Sylla, M. (2011). “Endectocides for malaria
408 control”. *Trends Parasitol*, **27**, 423–8.
- 409 Gates, B., & Chambers, R. (2015). “From aspiration to action: what will it take to end malaria?”.
410 <http://endmalaria2040.org/> (accessed Feb 18, 2016).
- 411 Global Malaria Programme (2014). “Control of residual malaria parasite transmission, Guidance note –
412 September”. Geneva: World Health Organization.
- 413 Global Malaria Programme (2015). World Malaria Report 2015. Geneva: World Health Organization.
- 414 Global Malaria Programme (2017). World Malaria Report 2017. Geneva: World Health Organization.
- 415 Govella, N. J. & Ferguson, H. (2012). “Why use of interventions targeting outdoor biting mosquitoes will
416 be necessary to achieve malaria elimination”. *Frontiers in Physiology*, **3**, 199.

- 417 Hill, N., Zhou, H. N., Wang, P., Guo, X., Carneiro, I. & Moore, S. J. (2014). “A household randomized,
418 controlled trial of the efficacy of 0.03% transfluthrin coils alone and in combination with long-
419 lasting insecticidal nets on the incidence of *Plasmodium falciparum* and *Plasmodium vivax*
420 malaria in Western Yunnan Province, China”. *Malar J*, **13**, 208.
- 421 Homan, T., Hiscox, A., Mweresa, C. K., Masiga, D., Mukabana, W. R., Oria, P., Maire, N., Pasquale, A.
422 D., Silkey, M., Alaii, J., Bousema, T., Leeuwis, C., Smith, T. A. & Takken, W. (2016). “The
423 effect of mass mosquito trapping on malaria transmission and disease burden (SolarMal): a
424 stepped-wedge cluster-randomised trial”. *The Lancet*, **388**(10050), 1193–201.
- 425 Innovation to Impact (I2I) (2016). <http://innovationtoimpact.org/>. (accessed Aug 20, 2016).
426
- 427 Innovative Vector Control Consortium (2016). IVCC Annual Report 2015-16. Liverpool: IVCC.
- 428 Killeen, G. F. (2014). “Characterizing, controlling and eliminating residual malaria transmission”. *Malar*
429 *J*, **13**, 330.
- 430 Kirby, M.J., Ameh, D., Bottomley, C., Green, C., Jawara, M., Milligan, P.J., Snell, P.C., Conway, D.J., &
431 Lindsay, S.W. (2009). “Effect of two different house screening interventions on exposure to
432 malaria vectors and on anaemia in children in The Gambia: a randomised controlled trial”. *The*
433 *Lancet*, **374**(9694), 998–1009.
434
- 435 Kiware, S. S., N. Chitnis, A. Tatarsky, S. Wu, H. M. S. Castellanos, R. Gosling, D. Smith and J. M.
436 Marshall (2017). "Attacking the mosquito on multiple fronts: Insights from the Vector Control
437 Optimization Model (VCOM) for malaria elimination." *PLoS One* **12**(2).
- 438 Knapp, J., Macdonald, M., Malone, D., Hamon, N. & Richardson, J. (2015). “Disruptive technology for
439 vector control: the Innovative Vector Control Consortium and the US Military join forces to
440 explore transformative insecticide application technology for mosquito control programmes”.
441 *Malar J*, **14**, 371.
- 442 Lawrence, C. E. & Croft, A. M. (2004). “Do mosquito coils prevent malaria? A systematic review of
443 trials”. *J Travel Med*, **11**, 92–6.
- 444 Lobo N.F., Achee N.L., & Syafruddin D. (2014). “Spatial repellent products for control of vector-borne
445 diseases - malaria - Indonesia (SR-M-IDR)”. University of Notre Dame.
446 <https://clinicaltrials.gov/show/NCT02294188> (accessed Jun 10, 2016).
- 447 Macintyre, K., Sosler, S., Letipila, F., Lochigan, M., Hassig, S., Omar, S. A. & Githure, J. (2003). “A new
448 tool for malaria prevention?: Results of a trial of permethrin-impregnated bedsheets (shukas) in
449 an area of unstable transmission”. *Int J Epidemiol*, **32**, 157-160.
- 450 Magris, M., Rubio-Palis, Y., Alexander, N., Ruiz, B., Galván, N., Frias, D., Blanco, M. & Lines, J.
451 (2007). “Community-randomized trial of lambda-cyhalothrin-treated hammock nets for malaria
452 control in Yanomami communities in the Amazon region of Venezuela”. *Trop Med Int Health*,
453 **12**, 392–403.
- 454 Malaria Policy Advisory Committee, WHO (2012). “Technical Expert Group (TEG) on malaria vector
455 control: Terms of Reference”. Geneva: World Health Organization.
456

- 457 Malaria Policy Advisory Committee, WHO (2015). "Innovation to Impact – WHO change plan for
458 strengthening innovation, quality and use of vector control tools". Geneva: World Health
459 Organization.
460
- 461 malERA Refresh Consultative Panel on Tools for Malaria Elimination (2017). "malERA: An updated
462 research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and
463 eradication." *PLoS One*, **14**(11).
- 464 Mbare, O., Lindsay, S. & Fillinger, U. (2014). "Pyriproxyfen for mosquito control: female sterilization or
465 horizontal transfer to oviposition substrates by *Anopheles gambiae sensu stricto* and *Culex*
466 *quinquefasciatus*". *Parasit Vectors*, **7**(1), 280.
- 467 Messenger, L. A., Matias, A., Manana, A. N., Stiles-Ocran, J. B., Knowles, S., Boakye, D. A., Coulibaly,
468 M. B., Larsen, M.-L., Traoré, A. S., Diallo, B., Konaté, M., Guindo, A., Traoré, S. F., Mulder, C.
469 E., Le, H., Kleinschmidt, I., & Rowland, M. (2012). "Multicentre studies of insecticide-treated
470 durable wall lining in Africa and South-East Asia: entomological efficacy and household
471 acceptability during one year of field use". *Malar J*, **11**(1), 1–13.
- 472 Mnzava, A.P., Macdonald, M.B., Knox, T.B., Temu, E.A. & Shiff, C.J. (2014). "Malaria vector control at
473 a crossroads: public health entomology and the drive to elimination". *Trans R Soc Trop Med Hyg*,
474 **108**(9), 550–4.
- 475 Mtove, G., Mugasa, J.P., Messenger, L.A., Malima, R.C., Mangesho, P., Magogo, F., Plucinski, M.,
476 Hashimu, R., Matowo, J., Shepard, D., Batengana, B., Cook, J., Emidi, B., Halasa, Y., Kaaya, R.,
477 Kihombo, A., Lindblade, K.A., Makenga, G., Mpangala, R., Mwambuli, A., Mzava, R., Mziray,
478 A., Olang, G., Oxborough, R.M., Seif, M., Sambu, E., Samuels, A., Sudi, W., Thomas, J.,
479 Weston, S., Alilio, M., Binkin, N., Gimnig, J., Kleinschmidt, I., McElroy, P., Moulton, L.H.,
480 Norris, L., Ruebush, T., Venkatesan, M., Rowland, M., Mosha, F.W., Kisinza, W.N. (2016). "The
481 effectiveness of non-pyrethroid insecticide-treated durable wall lining to control malaria in rural
482 Tanzania: study protocol for a two-armed cluster randomized trial". *BMC Public Health*, **16**(1),
483 633.
- 484 Ogoma, S. B., Moore, S. J. & Maia, M. F. (2012). "A systematic review of mosquito coils and passive
485 emanators: defining recommendations for spatial repellency testing methodologies". *Parasit*
486 *Vectors*, **5**, 287.
- 487 Pinder, M., Conteh, L., Jeffries, D., Jones, C., Knudsen, J., Kandeh, B., Jawara, M., Sicuri, E.,
488 D'Alessandro, U., Lindsay, S.W. (2016). "The RooPfs study to assess whether improved housing
489 provides additional protection against clinical malaria over current best practice in The Gambia:
490 study protocol for a randomized controlled study and ancillary studies". *Trials*, **17**(1), 275.
- 491 Ranson, H. & Lissenden, N. (2016). "Insecticide resistance in African *Anopheles* mosquitoes: a
492 worsening situation that needs urgent action to maintain malaria control". *Trends Parasitol*, **32**,
493 187-196.
- 494 Roll Back Malaria (2015). "Draft consensus statement on housing and malaria". Geneva: World Health
495 Organization.
- 496 Rowland, M., Durrani, N., Hewitt, S., Mohammed, N., Bourna, M. & Carneiro, I. (1999). "Permethrin-
497 treated protection against chaddars and top-sheets: appropriate technology for malaria in
498 Afghanistan and other complex emergencies". *Trans R Soc Trop Med Hyg*, **93**, 465–72.

- 499 Rowland, M., Durrani, N., Kenward, M., Mohammed, N., Urahman, H. & Hewitt, S. (2001). "Control of
500 malaria in Pakistan by applying deltamethrin insecticide to cattle: A community-randomised
501 trial". *Lancet*, **357**, 1837–41.
- 502 Sadasivaia, S., Tozan, Y. & Breman, J. (2007). "Dichlorodiphenyltrichloroethane (DDT) for indoor
503 residual spraying in Africa: how can it be used for malaria control?" *Am J Trop Med Hyg*, **77**,
504 249–63.
- 505
506 Snow, R. W., B. Sartorius, D. Kyalo, J. Maina, P. Amratia, C. W. Mundia, P. Bejon and A. M. Noor
507 (2017). "The prevalence of Plasmodium falciparum in sub-Saharan Africa since 1900." *Nature*
508 **550**(4677): 515-518.
- 509 Syafruddin, D., Bangs, M. J., Sidik, D., Elyazar, I., Asih, P. B., Chan, K., Nurleila, S., Nixon, C.,
510 Hendarto, J., Wahid, I., Ishak, H., Bogh, C., Grieco, J. P., Achee, N. L. & Baird, J. K. (2014).
511 "Impact of a spatial repellent on malaria incidence in two villages in Sumba, Indonesia". *Am J*
512 *Trop Med Hyg*, **91**, 1079–87.
- 513 Thang, N. D., Erhart, A., Speybroeck, N., Xa, N. X., Thanh, N. N., Van Ky, P., Hung, L. X., Thuan, L.
514 K., Coosemans, M. & D'alessandro, U. (2009). "Long-lasting insecticidal hammocks for
515 controlling forest malaria: A community-based trial in a rural area of Central Vietnam". *PLoS*
516 *ONE*, **4**.
- 517
518 The *Anopheles gambiae* 1000 Genomes Consortium (2017). "Genetic diversity of the African malaria
519 vector *Anopheles gambiae*." *Nature* **552**(1476-4687 (Electronic)): 96-100.
- 520 Thomas, M., Knols, B., & N'guessan, R. (2015). "Transition of eave tubes from concept to
521 implementation". Pennsylvania State University, 2015.
- 522 Tusting, L. S., Ippolito, M. M., Willey, B. A., Kleinschmidt, I., Dorsey, G., Gosling, R. D. & Lindsay, S.
523 W. (2015). "The evidence for improving housing to reduce malaria: a systematic review and
524 meta-analysis". *Malar J*, **14**, 209.
- 525 Tusting, L. S., Thwing, J., Sinclair, D., Fillinger, U., Gimnig, J., Bonner, K. E., Bottomley, C. & Lindsay,
526 S. W. (2013). "Mosquito larval source management for controlling malaria". *Cochrane Database*
527 *Syst Rev*, **8**, Cd008923.
- 528 Vontas, J., Moore, S., Kleinschmidt, I., Ranson, H., Lindsay, S., Lengeler, C., Hamon, N., Mclean, T. &
529 Hemingway, J. (2014). "Framework for rapid assessment and adoption of new vector control
530 tools". *Trends Parasitol*, **30**, 191–204.
- 531
532 Wagman, J., Gogue, C., Tynuv, K., Mihigo, J., Bankineza, E., Bah, M., Diallo, D., Saibu, A., Richardson,
533 J. H., Kone, D., Fomba, S., Bernson, J., Steketee, R., Slutsker, L. & Robertson, M. (2018). "An
534 observational analysis of the impact of indoor residual spraying with non-pyrethroid insecticides
535 on the incidence of malaria in Ségou Region, Mali: 2012–2015". *Malaria Journal*, **17**, 19.
- 536 Walshe, D. P., Garner, P., Abdel-Hameed Adeel, A. A., Pyke, G. H. & Burkot, T. (2013). "Larvivorous
537 fish for preventing malaria transmission". *Cochrane Database Syst Rev*, **12**, Cd008090.
- 538 WHO Vector Control Advisory Group (2013). "Report on the first meeting of the WHO Vector Control
539 Advisory Group". Geneva: World Health Organization Vector Control Advisory Group.

- 540 WHO Vector Control Advisory Group (2014). “Report on the second meeting of the WHO Vector
541 Control Advisory Group”. Geneva: World Health Organization Vector Control Advisory Group.
- 542 Wilson, A. L., Boelaert, M., Kleinschmidt, I., Pinder, M., Scott, T. W., Tusting, L. S. & Lindsay, S. W.
543 (2015). “Evidence-based vector control? Improving the quality of vector control trials”. *Trends*
544 *Parasitol*, **8**, 380–90.
- 545 Wilson, A. L., Chen-Hussey, V., Logan, J. G. & Lindsay, S. W. (2014). “Are topical insect repellents
546 effective against malaria in endemic populations? A systematic review and meta-analysis”. *Malar*
547 *J*, **13**, 446.
- 548 World Health Organization (2009). “Development of a global action plan for integrated vector
549 management (IVM)”. Geneva: World Health Organization.
550
- 551 World Health Organization (2015). “Global Technical Strategy for Malaria 2016–2030”. Geneva: World
552 Health Organization. <http://www.who.int/malaria/publications/atoz/9789241564991/en/> (accessed
553 May 27, 2016).
- 554 World Health Organization (2017). “Global Vector Control Response 2017–2030”. Geneva: World
555 Health Organization. [http://apps.who.int/iris/bitstream/10665/259205/1/9789241512978-](http://apps.who.int/iris/bitstream/10665/259205/1/9789241512978-eng.pdf?ua=1)
556 [eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/259205/1/9789241512978-eng.pdf?ua=1) (accessed January 10, 2018).
- 557




Figure 1. Study flow for a systematic review of the evidence for 21 malaria vector control tools

*Other sources: reference lists of included studies

558

559




Figure 2. Frequency of eligible studies of 21 malaria vector control tools (VCTs), stratified by study design. A: studies with any outcome of interest; B: studies with diagnostically confirmed malaria incidence or prevalence. †Only systematic reviews with AMSTAR (A Measurement Tool to Assess Systematic Reviews) scores of $\geq 50\%$ are included. *For topical repellents, larval source management and mosquito-proofed housing, the frequency of studies represents all eligible studies within the referenced systematic review. For all other VCTs, the frequency of studies represents all eligible studies within the present review.

560

561

Table 1. Description of malaria vector control tools (VCTs) included in the review

VCT*	Description	Primary mode(s) of action against malaria vectors
<i>Interventions targeting immature mosquitoes</i>		
Larval source management (LSM)	Management of potential larval habitats to prevent the development of immature mosquitoes into adults; includes habitat modification and manipulation; biological control with natural enemies of mosquitoes; aerial and ground-based larviciding.	Reduced adult emergence and density
<i>Interventions targeting adult mosquitoes</i>		
Adult sterilization by contamination	Sterilization of adult mosquitoes through contact with pyriproxyfen, using delivery mechanisms other than ITNs.	Reduced adult reproduction and density
Other attract-and-kill mechanisms	Traps and targets that attract blood-seeking mosquitoes using a combination of odours from humans and other mammals (e.g. carbon dioxide, L-lactic acid, ammonia and short-chain fatty acids), some of which are treated with chemical or biological insecticides (e.g. pyrethroids organophosphates, entomopathogenic fungi).	Increased adult mortality
Attractive toxic sugar baits (ATSB)	Lethal traps that exploit sugar-feeding behaviour to attract mosquitoes using sugar and that contain insecticides (e.g. boric acid).	Reduced adult survival and density
Biological control of adult vector capacity/longevity	Infection of adult mosquitoes with bacteria (e.g. <i>Wolbachia</i> spp) or entomopathogenic fungi to reduce longevity and/or up-regulate immune genes.	Reduced adult survival and infection rates
Eave tubes and eave baffles	A variety of different eave (space between the roof and walls of a house or structure) modifications that kill mosquitoes with traps or insecticides when they try to enter or exit from those houses.	Reduced adult survival and density
Endectocide administration in humans	Mass administration to humans of a systemic insecticide, sometimes described as an endectocide (e.g. ivermectin).	Reduced adult survival and density
Endectocide administration in livestock	Mass administration to livestock of an endectocide (e.g. ivermectin, fipronil, eprinomectin) to kill zoophagic <i>Anopheles</i> .	Reduced adult survival and density
Genetic modification	Mass release of mosquitoes, which are genetically modified (e.g. homing endonuclease genes (HEG) and RNA interference (RNAi); radiation-or chemo-sterilized males (sterile insect technique, SIT)).	Reduced adult reproduction and density and/or reduced competence as the primary host for malaria parasites
Insecticide-treated clothing and blankets	Clothing and/or blankets treated with an insecticide (e.g. permethrin)	Reduced adult survival and density, as well as human exposure to biting
Insecticide-treated durable wall linings	Thin, durable sheets of insecticide-treated cloths that cover interior wall surfaces; insecticides remain efficacious for a period of three to four years	Reduced adult survival and density
Insecticide-treated fencing	Insecticide-treated netting used as fencing around livestock enclosures	Reduced adult survival and density
Insecticide-treated hammocks	Hammocks treated with an insecticide (e.g. permethrin)	Reduced adult survival and density, as well as human exposure to biting
Insecticide-treated livestock	Application of topical insecticide (e.g. pyrethroids) or entomopathogenic fungus to livestock to kill zoophilic mosquitoes	Reduced adult survival and density
Mosquito-proofed housing	Houses with features that reduce mosquito house entry (e.g. use of modern wall, floor and roof materials, use of insecticide-treated or untreated door and window screens, presence of a ceiling).	Reduced human exposure to biting mosquitoes
Push-pull systems	The simultaneous use of attractive and repellent volatiles (e.g. baited trap near home with insecticide-treated fabric in eaves).	Reduced adult survival and density, as well as human exposure to biting
Space spraying (ground application)	Liquid insecticide (e.g. pyrethroids, malathion) dispersed as fine droplets in the air (either thermal or cold fog) using hand-held or vehicle-mounted devices; can be used indoors or outdoors. Includes targeted spraying of male mating swarms.	Reduced adult survival and density
Spatial repellents	Products that release chemical active ingredients into the air as vapours, which repel, incapacitate or kill adult mosquitoes (e.g. mosquito coils and emanators to release pyrethroids).	Reduced human biting, increased adult mortality
Topical repellents	Insect repellent (e.g. DEET, citronella, picaridin, lemon eucalyptus) applied to the skin to provide personal protection from biting.	Reduced human biting
Zooprophylaxis	Presence of animals/livestock to divert vector biting away from humans (which if applied at the individual level may also result in increased individual human risk, known as zoopotential).	Reduced exposure of humans to infectious adult mosquitoes and mosquitoes to infectious human beings
<i>Interventions targeting immature mosquitoes via adults</i>		
Larvicide application by auto-dissemination	Delivery of larvicide (e.g. pyriproxyfen) to larval habitats by adult female mosquitoes that are exposed to contaminated artificial resting sites	Reduced adult density

*VCTs excluded from the study: adult mosquito traps with no kill mechanism, aerial application of larvicide or adulticide, electronic mosquito repellents, indoor residual spraying, insecticide-treated curtains and nets, insecticide-treated paint, insecticide-treated plastic sheeting in tents or in temporary shelters, insecticide-treated tents, live plants as spatial repellents, nanoparticles for larviciding. Additionally, studies of the insecticidal properties of compounds and formulations were excluded.

Table 2. Criteria for inclusion or exclusion of studies

	Inclusion Criteria	Exclusion Criteria
Study design	Systematic reviews of experimental studies Phase III studies: randomized controlled (RCT), controlled before-and-after (CBA) [*] , cross-over [†] , interrupted time-series [‡] Phase II studies [§] : small-scale, semi-field, experimental hut Phase I studies: laboratory Observational studies: case-control, cohort, cross-sectional	Review articles Opinion papers Modelling studies
Intervention	Any malaria vector control tool (VCT) targeting <i>Anopheles</i> mosquitoes described in Table 1	Adult mosquito traps with no kill mechanism, electronic mosquito repellents, indoor residual spraying (IRS), insecticide-treated curtains and nets, insecticide-treated paint, insecticide-treated plastic sheeting in tents or in temporary shelters, insecticide-treated nets (ITNs), insecticide-treated tents, live plants as spatial repellents, studies of the insecticidal properties of compounds and formulations
Primary epidemiological outcomes	Malaria incidence and infection prevalence in any age group, diagnostically confirmed by microscopy or rapid diagnostic test	Malaria incidence and infection prevalence not diagnostically confirmed by rapid diagnostic test or microscopy
Primary entomological outcomes	Entomological inoculation rate (EIR) [¶] Human biting rate (HBR) [‡] Adult mosquito density metrics other than HBR ^{**}	
Secondary entomological outcomes ^{††}	Additional entomological outcomes appropriate to the intervention including adult mosquito fecundity, adult mosquito fitness, adult emergence rates, knockdown post-exposure, blood-feeding inhibition	
Dates	Studies published from January 1, 1980 to September 28, 2015	Studies published before January 1, 1980 and after September 28, 2015

^{*}Controlled before-and-after studies: if arms were comparable at baseline, there were at least two units per arm, follow-up periods were the same for the intervention and control arms, and baseline characteristics were comparable between arms.

[†]Cross-over studies: if there was adequate allowance for washout (time between two intervention periods to allow the effect of the first intervention to be washed out).

[‡]Interrupted time-series studies: if data were collected during at least three time points pre- and post- follow-up, if no co-interventions were introduced after baseline data collection and if the intervention was implemented for a clearly defined period.

[§]Phase III studies were differentiated from Phase II studies in being conducted in real-life settings (not semi-field or experimental hut systems) and having a minimum intervention period of one transmission season or year.

[¶]Entomological inoculation rate (EIR): the number of bites by sporozoite-infected mosquitoes per person per unit time.

[‡]Human biting rate (HBR): the number of host-seeking mosquitoes attempting to attack humans per person or house per time period.

^{**}Density measures other than HBR (e.g. number of mosquitoes per person, house or catch), measured directly using human landing catches or indirectly using light traps, knock-down catches or other methods of biting rate determination.

^{††}Secondary entomological outcomes, such as adult mosquito fecundity, adult mosquito fitness, adult emergence rates, knockdown post-exposure, blood-feeding inhibition, were included where reported in Phase I and II studies.